Aytu BioPharma (NASDAQ:AYTU) Announces Earnings Results, Misses Expectations By $0.02 EPS

Aytu BioPharma (NASDAQ:AYTU) posted its earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02), FiscalAI reports. Aytu BioPharma had a positive return on equity of 13.77% and a negative net margin of 20.43%.The firm had revenue of $13.89 million during the quarter, compared to analysts’ expectations of $17.92 million.

Aytu BioPharma Price Performance

NASDAQ AYTU traded up $0.22 on Friday, reaching $2.28. 96,841 shares of the company’s stock traded hands, compared to its average volume of 487,399. The stock has a market cap of $23.18 million, a PE ratio of -0.81 and a beta of 0.25. Aytu BioPharma has a 12 month low of $0.95 and a 12 month high of $2.82. The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $2.12. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.26 and a quick ratio of 1.07.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently bought a new stake in Aytu BioPharma stock. Dimensional Fund Advisors LP bought a new position in Aytu BioPharma Inc. (NASDAQ:AYTU) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 30,964 shares of the company’s stock, valued at approximately $58,000. Dimensional Fund Advisors LP owned 0.30% of Aytu BioPharma as of its most recent SEC filing. Institutional investors and hedge funds own 33.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AYTU shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Tuesday, October 14th. Wall Street Zen cut Aytu BioPharma from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Ascendiant Capital Markets lifted their price target on Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a research report on Thursday, September 25th. Zacks Research cut shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Friday, October 10th. Finally, Maxim Group lowered their target price on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.17.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.